SEC Filing Summary: AIKIDO PHARMA INC. (AIKI)
Business Context and Reporting Period
This Form 8-K was filed on November 2, 2021, by AIKIDO PHARMA INC., a Delaware corporation. The filing addresses the status of the Company's scheduled annual meeting of stockholders originally set for November 3, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events regarding the annual meeting.
Material Changes and Events
- Meeting Postponement: The Company determined it could not convene the annual meeting on November 3, 2021, due to an insufficient number of votes to form a quorum (requiring >50% of outstanding shares).
- Vote Status: As of the August 17, 2021 record date, the Company had received votes from approximately 48% of shares outstanding.
- Quorum Requirement: The Company needs an additional approximately 3% of votes to reach the quorum threshold.
- Rescheduling: The annual meeting has been rescheduled for 12:00 p.m. Eastern Standard Time on December 8, 2021.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operations, or specific risk factors beyond the immediate contingency of failing to achieve a quorum. The primary risk addressed is the inability to conduct shareholder business without the required vote count.
Key Facts for Investor Verification
- Verify the new meeting date of December 8, 2021, and confirm access details via the Definitive Proxy Statement filed on August 26, 2021.
- Monitor the vote count to ensure the additional ~3% required for a quorum is obtained prior to the rescheduled date.
- Confirm that the rescheduled meeting will proceed under the same agenda and proxy instructions as the original filing.